In conclusions, the present study demonstrates that Rho-kinase inhibition ameliorates metabolic disorders through activation of the LKB1/AMPK pathway in mice, suggesting that Rho-kinase could be a novel therapeutic target of metabolic disorders. Here, PRKAA2 is linked to Other metabolic disease.